Search Results
Oct 19, 2025, 20:10 ET Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 in 65 participants with obesity or overweight. - The
More news about: Ascletis Pharma Inc.
Oct 19, 2025, 20:10 ET 歌禮完成小分子GLP-1R激動劑ASC30治療肥胖症的每月一次皮下儲庫型治療制劑的美國IIa期研究受試者入組
12 周 IIa 期研究評估小分子 GLP-1 受體（ GLP-1R ）激動劑 ASC30 每月一次皮下儲庫型（
More news about: 歌禮製藥有限公司
Oct 17, 2025, 17:39 ET FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
Rybelsus® (semaglutide) tablets 7 mg or 14 mg, the only FDA-approved oral GLP-1 medicine available, now indicated to reduce the risk of major adverse cardiovascular events (MACE)
More news about: Novo Nordisk
Oct 17, 2025, 17:15 ET FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
Rybelsus® (semaglutide) tablets 7 mg or 14 mg, the only FDA-approved oral GLP-1 medicine available, now indicated to reduce the risk of major adverse cardiovascular events (MACE) such as CV death, heart attack, or stroke in adults with type 2 diabetes
More news about: Novo Nordisk
Oct 17, 2025, 10:59 ET Sunlight.com Survey Finds 41% of GLP-1 Users Credit Career Advancement to Weight Loss
report from Sunlight.com reveals that weight loss from GLP-1 medications is helping Americans gain more than just health benefits — it's transforming their professional and social lives. The October 2025 survey of 984 GLP-1 users found that 41% credit their weight loss with career
More news about: Sunlight
Oct 17, 2025, 06:22 ET Weekly Recap: 14 Health Press Releases You Need to See
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in
More news about: PR Newswire
Oct 16, 2025, 17:09 ET CVS Health Helps Improve Access to More Affordable Fertility Treatments
by leveraging its strengths in pharmacy and improving access through multiple delivery channels in healthcare, as CVS Health also done with GLP-1 drugs. When will the TrumpRx Fertility program be available?
More news about: CVS Health
Oct 16, 2025, 08:00 ET Beyond GLP-1s: Withings Health Solutions Unveils Best Practices for Obesity Care Management Programs
decisions and make obesity care truly sustainable." Making Monitoring Central to GLP-1 CareAs GLP-1 drugs surge in popularity, sustainable weight and obesity care requires integrating monitoring, skill-building for lifestyle
More news about: Withings Health Solutions
Oct 15, 2025, 16:05 ET Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025
therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is
More news about: Viking Therapeutics, Inc.
Oct 15, 2025, 11:50 ET Mission Foods Expands "Better For You" Line with Zero Net Carbs Spinach Tortillas
increasing fiber or fueling up." GLP-1 friendly and nutrient-dense GLP-1 lifestyles are reshaping how millions of Americans eat by encouraging more fiber- and protein-rich
More news about: Mission Foods
Oct 15, 2025, 09:01 ET Carrum Health Doubles Covered Lives as Employers Confront Record Healthcare Costs
on Health (BGH), Mercer, WTW, Aon, Segal}, following an estimated 8% growth in 2025 Soaring drug costs driven by GLP-1 weight loss drugs and cancer therapies Looming Medicaid budget cuts that will further shift costs to the commercial market
More news about: Carrum Health
Oct 15, 2025, 06:45 ET Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther. 2024 Apr;15(4):819-832.
More news about: Eli Lilly and Company
Oct 15, 2025, 06:00 ET Global Wellness Summit Unveils Packed 3-Day Agenda for 2025 Conference in Dubai, November 18-21
Summit offers unparalleled networking opportunities, including 90 hosted "table topic" luncheons with industry leaders discussing everything from how GLP-1s are transforming wellness to the latest frontiers in brain health. There will also be expert-led, intimate after-dinner conversations on topics like
More news about: Global Wellness Summit
Oct 14, 2025, 23:00 ET HistoIndex to debut FibroSIGHT™ Plus and showcase latest scientific findings at AASLD The Liver Meeting® 2025
Loomba Title: Combination therapy in Metabolic Dysfunction – associated Steatohepatitis: GLP-1R Agonist with othersPresenter: Li Hui
More news about: Histoindex Pte. Ltd.
Oct 14, 2025, 12:29 ET Smart Snacking Part of a Healthy Diet
peanuts and peanut butter into an individual's diet may help with weight loss. Peanut consumption may also support those who are taking a GLP-1 medication. "Oftentimes snacking is an attempt to hold yourself over between meals," says Dr. Sterling.
More news about: The Peanut Institute
Oct 14, 2025, 10:00 ET Everbright Health Launches with $7M Investment and 75 Provider Partners to Expand Access to Advanced Mental Health Interventions
psychiatric interventions are on the cusp of becoming mainstream care. With remarkable outcomes, we believe they are poised to have their own 'GLP-1' moment for market adoption." About Everbright Everbright
More news about: Everbright Health
Oct 14, 2025, 08:31 ET MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference
analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing
More news about: MetaVia Inc.
Oct 14, 2025, 08:00 ET Rivus Pharmaceuticals to Present Clinical Data from Phase 2a M-ACCEL Trial of HU6 in MASH as Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025
Abstract Title: Oral Controlled-Metabolic Accelerator Drives Fat-Specific Weight Loss and Augments GLP-1 EffectAbstract Number: 121Format: Poster PresentationPresenter: Sol Collado, Ph.D., Senior Director,
More news about: Rivus Pharmaceuticals
Oct 14, 2025, 06:00 ET 歌禮與中國國家藥品監督管理局完成地尼法司他（ASC40）的新藥上市申請前溝通
研 小分子 GLP-1 受體 （ GLP-1R ） 激 動劑
More news about: 歌禮製藥有限公司
Oct 14, 2025, 06:00 ET Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
Ultra-Long-Acting Platform (ULAP) technologies, Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy
More news about: Ascletis Pharma Inc.
Oct 14, 2025, 06:00 ET Twin Health and Peloton Partner to Transform Metabolic Health
content. Together, we help members achieve lasting health outcomes and sustain muscle mass while safely reducing or discontinuing costly medications like GLP-1s, without rebound weight gain." This comes on the heels of the release of a landmark
More news about: Twin Health
Oct 13, 2025, 17:16 ET Healing Healthcare: Specialdocs Inspires Change at the 2025 Concierge Medicine Forum
seamless grand opening. Weight Loss Management in the GLP-1 Era: A concierge medicine approach to success. Map Your Route to Concierge
More news about: Specialdocs Consultants
Oct 13, 2025, 08:46 ET Fresh Thyme Market Reveals 2026 Food Trend Forecast
Neuro Gum Focus Gummies 10. GLP-1 Lifestyle Support: With the rise of GLP-1 medications, shoppers are prioritizing nutrient-rich foods that support metabolism, satiety, and balanced nutrition.
More news about: Fresh Thyme
Oct 12, 2025, 20:10 ET Ascletis Selects a Best-In-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development
respectively. - ASC35 was approximately 4-fold more potent than tirzepatide for both GLP-1 receptor (GLP-1R) and GIP receptor (GIPR) in vitro. - ASC35 demonstrated
More news about: Ascletis Pharma Inc.
Oct 11, 2025, 08:45 ET C-Ray Therapeutics (Chengdu) Co., Ltd Congratulates Partner Biokin Pharmaceutical on NMPA IND Approval of First Proprietary ARC Drug [177Lu]-BL-ARC001
IND filing to clinical and commercial supply. Headquartered in Chengdu Medical City, C-Ray operates a 28,000 m² world-class GMP facility and GLP-like nonclinical research center. With more than 50 projects delivered and ongoing, C-Ray is building an open innovation platform to accelerate theranostic
More news about: C Ray Therapeutics